340B and Pharmaceutical Access
The 340B Drug Pricing Program supports safety net providers, such as children's hospitals, in their mission to serve low-income, uninsured and under-insured patients.
CHA Responds to 340B Draft Bill and Request for Information
The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.
CHA Response to Drug Shortages White Paper
CHA submitted comments on a drug shortages white paper to highlight pediatric health care needs.
CHA Response to Cell and Gene Therapy RFI
Cell and gene therapies have the potential to address unmet pediatric medical needs, reduce the need for costly chronic care, and help address health disparities.
CHA Submits Comments for Energy and Commerce Discussion Draft on Drug Shortages
CHA submitted a comment letter to the Energy and Commerce Committee to highlight pediatric needs when addressing drug shortages.
CHA Responds to Drug Shortages Request for Information
CHA submitted a response to the bicameral drug shortages request for information (RFI) to highlight pediatric health care needs.
CHA Responds to Senate 340B Request for Information
The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.
CHA Submits Comments on 340B Proposed Rule
Children’s Hospital Association sent a comment letter to the Centers for Medicare and Medicaid Services on the 340B remedy proposed rule.
CHA Submits Comments on FDA Drug Shortage Guidance
Children’s Hospital Association sends a comment letter to the FDA on draft drug shortage guidance to highlight the need for an efficient pediatric supply chain.
CHA Sends Letter to DEA on Tele-prescribing for Controlled Substances
Children’s Hospital Association sends a letter to the DEA supporting their policy change to better address children’s unique health care needs.
For the Record
View CHA communications to federal policymakers such as statements for the record, RFI responses, regulatory comment letters and more.
